Das Antiphospholipid-Syndrom (APS) ist ein bedeutender Risikofaktor für Schwangerschaftskomplikationen, doch seine Diagnose bleibt eine Herausforderung. Jüngste Fortschritte in der APS-Diagnostik liefern tiefere Einblicke in seine Rolle bei wiederholtem Schwangerschaftsverlust und Präeklampsie. Durch innovative Biomarkerforschung und verfeinerte Testmethoden wird die Diagnosesicherheit verbessert, sodass Risikopatientinnen präziser identifiziert und gezielt behandelt werden können. Erfahren Sie mehr über die neuesten Entwicklungen in der APS-Diagnostik und deren Auswirkungen auf die mütterliche und fetale Gesundheit.

Antiphospholipid Syndrome (APS) is a major risk factor for pregnancy complications, yet diagnosing it remains challenging. Recent advancements in APS diagnostics provide deeper insights into its role in recurrent pregnancy loss and preeclampsia. Cutting-edge biomarker research and refined testing methods are improving accuracy, helping clinicians better identify at-risk patients and tailor treatment strategies. Discover the latest developments in APS diagnostics and their impact on maternal and fetal health.

Stay Ahead in Diagnostics and Subscribe to Our Newsletter In the fast-evolving field of diagnostics, staying informed is key. With the Medipan & GA Generic Assays newsletter, you gain exclusive access to our latest advancements, research insights, and innovative solutions in autoimmune and infectious disease diagnostics.  Why Subscribe?  As a leader in in-vitro diagnostics, we […]

The International Consensus on ANA Patterns (ICAP) has taken another significant step in the continuous advancement to promote harmonization and understanding in antinuclear antibodies (ANA) of the HEp-2 IFA. As previously anticipated, in the ongoing update of the ANA pattern classification, two newly identified patterns, AC-30 and AC-31, have been incorporated into the ICAP nomenclature […]

A recent outbreak of Guillain-Barré Syndrome (GBS) in Pune, India, has seen approximately 160 reported cases since early January. The outbreak has been linked to Campylobacter jejuni, a foodborne pathogen and one of the leading causes of GBS worldwide [1]. Understanding Guillain-Barré Syndrome and Its Triggers GBS is a rare neurological autoimmune disease in which […]

Extended Shelf Life for Our RIA Kits We are pleased to announce that our optimized production processes now ensure you receive RIA Kits SELco® TSH Rapid, SELco® Tg 1 Step, and SELco® Calcitonin with an extended shelf life of additional two weeks. Thanks to these improvements, we now complete the production process two weeks earlier, […]

Product Catalog | 2025 We are delighted to present the 2025 Product Catalog, showcasing our extensive portfolio of diagnostic solutions for autoimmune diseases. Designed to support healthcare professionals, researchers, and partners, our catalog provides the tools and insights you need to advance diagnostics and enhance patient care. What’s inside? ✅ Detailed product descriptions: Explore our […]

February 3 – 6, 2025 | Dubai World Trade Centre | Dubai, United Arab Emirates We are excited to announce our participation in Medlab Middle East 2025, taking place from February 3 – 6, 2025, at the Dubai World Trade Centre. With 30,000+ attendees, 900 exhibitors, and professionals from 180+ countries, Medlab offers an excellent […]

09 – 12, September 2025 | Dresden Fair | Dresden, Germany 17th Dresdner Symposium on Autoantibodies (GFID) 2025 We are excited to announce that Medipan & GA Generic Assays will once again be exhibiting at the 17th Dresden Symposium on Autoantibodies (GFID) in 2025! The GFID Symposium is a key event for experts in the […]

November 17 – 20, 2025 | Messe Düsseldorf | Düsseldorf, Germany MEDICA 2025 MEDICA is one of the world’s largest medical B2B trade fairs and a key meeting point for professionals in the healthcare industry. With over 40 years of history, the event provides an excellent platform to discover the latest innovations in medical technology. […]